|
|
|
ADXS - Advaxis, Inc.
Advaxis
is primarily focused on the development of immunotherapy products that
utilize its proprietary Listeria monocytogenes (Lm) platform to
stimulate the immune system to target and destroy cancer cells. The
company's lead product candidate is axalimogene filolisbac (AXAL),
which is being developed for the treatment of several types of cancer,
including cervical, head and neck, and anal cancer.
In addition
to AXAL, Advaxis has a pipeline of other Lm-based immunotherapy
products in development, including ADXS-HOT, which targets cancers
associated with human papillomavirus (HPV), and ADXS-504, which
targets prostate cancer.
The company has reported financial
results for the third quarter of 2021, reporting a net loss of $6.9
million, compared to a net loss of $6.4 million in the same period in
the previous year. Advaxis reported cash and cash equivalents of $31.4
million as of September 30, 2021.
Advaxis has been focused on
advancing its pipeline of immunotherapy products and entering into
partnerships and collaborations with other companies. In November
2021, the company announced that it had entered into a clinical
collaboration with Merck to evaluate the safety and efficacy of a
combination therapy of AXAL and Merck's anti-PD-1 therapy for the
treatment of cervical cancer.
However, the company's financial
performance and operations may be impacted by various factors,
including the outcome of clinical trials, regulatory changes, and
competition in the biotechnology industry. In addition, the success of
immunotherapy products may be affected by factors such as the ability
of the immune system to respond to treatment and the presence of
tumors with resistance to therapy.
Overall, Advaxis, Inc. is a
clinical-stage biotechnology company focused on the development and
commercialization of immunotherapy products for the treatment of
cancer. The company has a pipeline of Lm-based immunotherapy products
in development and has entered into partnerships and collaborations to
advance its research and development efforts. However, the company's
financial performance and operations are subject to various risks and
uncertainties associated with the biotechnology industry and the
success of immunotherap
|
|
|
|
|
